P2318
Anti-Pseudomonas Exotoxin A antibody produced in rabbit
whole antiserum
Synonym(s):
Anti-ETA
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Conjugate:
unconjugated
Clone:
polyclonal
Application:
DB, ELISA (i)
Citations:
19
biological source
rabbit
conjugate
unconjugated
antibody form
whole antiserum
antibody product type
primary antibodies
clone
polyclonal
contains
15 mM sodium azide
species reactivity
(Pseudomonas aeruginosa)
technique(s)
dot blot: 1:20,000, indirect ELISA: 1:250,000
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
Pseudomonas aeruginosa PAO1 ... toxA(877850)
General description
Reacts against Pseudomonas exotoxin A, but shows no reaction against Staphylococcal enterotoxin A, Cholera toxin, and Staphylococcal enterotoxin B. The product has not been tested for neutralization potency against active Pseudomonas exotoxin A.
Immunogen
exotoxin A from Pseudomonas aeruginosa.
Application
Anti-Pseudomonas Exotoxin A antibody has been used in in vitro serum stability of fusion toxins and binding of targeted toxins.
Anti-Pseudomonas exotoxin A antibody produced in rabbit has been used:
- in the in vitro analysis of the stability of fusion toxins in serum
- to construct an epidermal growth factor receptor (EGFR)-targeted toxin to study its toxicity on Swiss mouse embryo NIH-3T3 cells transfected with human EGFR
- in the determination of the in vivo half-life of immunotoxins in serum
Biochem/physiol Actions
Pseudomonas exotoxin A is secreted by Pseudomonas aeruginosa and has potent cytotoxic effects. Exotoxin A enters the cells by receptor-mediated endocytosis, translocates to the cytoplasm and inhibits protein synthesis by ADP-ribosylating factor 2. Chimeric exotoxin A has applications in gene treatment of various diseases and probable treatment for cancer.
Physical form
This product is supplied as a liquid containing 15 mM sodium azide as preservative.
Preparation Note
For continuous use, store at 2-8 °C for up to one month. For extended storage, the solution may be frozen in working aliquots. Repeated freezing and thawing is not recommended. Storage in "frost-free" freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
常规特殊物品
动植物来源生物产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Alexander N Wein et al.
Journal of medicinal chemistry, 55(18), 7998-8006 (2012-09-08)
Protective antigen (PA), lethal factor, and edema factor, the protein toxins of Bacillus anthracis , are among its most important virulence factors and play a key role in infection. We performed a virtual ligand screen of a library of 10000
Moritz Bewarder et al.
Cancer immunology, immunotherapy : CII, 69(8), 1535-1548 (2020-04-18)
With an infection rate of 60-90%, the human cytomegalovirus (HCMV) is very common among adults but normally causes no symptoms. When T cell-mediated immunity is compromised, HCMV reactivation can lead to increased morbidity and mortality. HCMV antigens are processed and
Fusion of an albumin-binding domain extends the half-life of immunotoxins
Guo R, et al.
International Journal of Pharmaceutics, 511(1), 538-549 (2016)
Alexander Weng et al.
Molecular oncology, 6(3), 323-332 (2012-02-09)
Tumor-targeting protein toxins are composed of a toxic enzyme coupled to a specific cell binding domain that targets cancer-associated antigens. The anti-tumor treatment by targeted toxins is accompanied by dose-limiting side effects. The future prospects of targeted toxins for therapeutic
Daejin Lim et al.
Oncotarget, 8(23), 37550-37560 (2017-05-06)
The anticancer strategy underlying the use of immunotoxins is as follows: the cancer-binding domain delivers the toxin to a cancer cell, after which the toxin enters and kills the cell. TGFα-PE38 is an immunotoxin comprising transforming growth factor alpha (TGFα)
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service